Extended-Release Drugs Market Forecast Highlights Expansion From $77.91 Billion To $126.89 Billion Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Extended-Release Drugs Market Revenue Outlook: What CAGR Is Expected Through 2030?
In recent years, the market for extended-release medications has experienced rapid expansion. Projected to rise from $69.63 billion in 2025 to $77.92 billion in 2026, it is expected to achieve a compound annual growth rate (CAGR) of 11.9%. This historic growth has been driven by factors such as the increasing incidence of chronic conditions, a growing preference for patient-focused drug formulations, the inherent drawbacks of immediate-release options, higher healthcare spending, and innovations in pharmaceutical excipients.
The market for extended-release medications is projected to experience significant expansion in the near future. By 2030, it will reach a size of $126.89 billion, achieving a compound annual growth rate (CAGR) of 13.0%. This anticipated growth during the forecast period can be linked to the rise of precision medicine, a greater use of oral controlled-release formulations, the growth of hospital and retail pharmacy networks, an increase in the elderly population, and investments in innovative delivery technologies. Key developments shaping this period consist of personalized dosing schedules, sophisticated drug delivery platforms, strategies to improve patient adherence, new formulation methods, and combination therapies with extended-release features.
Download A Free Sample Report For Comprehensive Market Insights:
Extended-Release Drugs Market Demand Drivers: What Is Fueling Industry Growth?
The anticipated rise in chronic diseases is set to boost the extended-release drug market in the coming years. Chronic diseases are those that persist for a year or longer, requiring ongoing medical attention, limiting daily activities, or both. Examples include heart disease, cancer, obesity, and diabetes. Extended-release drug systems are crafted to ensure a steady medication level in the body over an extended timeframe, supporting consistent therapeutic outcomes and minimizing the drug level fluctuations often seen with immediate-release alternatives. In January 2023, data from the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, indicated that by 2050, the number of people aged 50 and above with at least one chronic condition is expected to increase by 99.5%, reaching 142.66 million. Consequently, the growing prevalence of chronic illnesses is fueling expansion in the extended-release drug market.
Extended-Release Drugs Market Segments: Where Are The Largest Growth Opportunities?
The extended-release drugs market covered in this report is segmented –
1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores
Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems
Extended-Release Drugs Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the extended-release drugs market are concentrating on the creation of advanced formulations, including next-generation extended-release tablets, to strengthen their product portfolios and secure a market edge. These tablets represent a specialized class of pharmaceuticals designed to dispense their active components slowly over a prolonged timeframe. In February 2023, for example, Teva Pharmaceutical Industries Ltd., headquartered in Israel, secured U.S. Food and Drug Administration (FDA) clearance for austedo XR (deutetrabenazine). This medication is indicated for managing chorea and tardive dyskinesia associated with Huntington disease in adults, and it is supplied in 6, 12, and 24 mg strengths. Following the approval of austedo XR, patients facing tardive dyskinesia or Huntington disease-related chorea have gained access to an additional effective therapy, taken just once daily. The launch of austedo XR marks a notable advancement in treating these conditions, offering a convenient and impactful solution for individuals living with such movement disorders.
Extended-Release Drugs Market Major Participants And Competitive Dynamics
Major companies operating in the extended-release drugs market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Watson Pharmaceuticals Inc.
Access The Complete Extended-Release Drugs Market Report:
Extended-Release Drugs Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the extended-release drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
